Evidence map›Paper›PMID 37858242›Full record

ArticleJournal of nanobiotechnology2023

Engineering antioxidant ceria-zirconia nanomedicines for alleviating podocyte injury in rats with adriamycin-induced nephrotic syndrome.

Lili Liu, Meiqi Chang, Rong Yang, Li Ding, Yu Chen, Yulin Kang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 1 country.

Lili LiuSchool of Medicine, Anhui University of Science and Technology, Huainan, 232000, People's Republic of China.
Meiqi ChangLaboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, People's Republic of China.
Rong YangDepartment of Pediatrics, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, People's Republic of China.
Li DingDepartment of Medical Ultrasound, National Clinical Research Center of Interventional Medicine, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Tongji University School of Medicine, Tongji University, Shanghai, 200072, People's Republic of China. dingli@tongji.edu.cn.
Yu ChenMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, People's Republic of China. chenyuedu@shu.edu.cn.
Yulin KangDepartment of Nephrology and Rheumatology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, People's Republic of China. kangyl@shchildren.com.cn.
Anhui University of Science and Technology · CNShanghai Children's Hospital · CNShanghai Tenth People's Hospital · CNShanghai University · CNShanghai University of Traditional Chinese Medicine · CNTongji University · CN

Funding

National Facility for Translational Medicine of China TMSK2021-115National Natural Science Foundation of China 82271997Science and Technology Commission of Shanghai Municipality 23ZR1452900
6 · The paper itself

Abstract

backgroundPrimary nephrotic syndrome (PNS) is characterized by edema, heavy proteinuria, hypoalbuminemia and hyperlipidemia. Moreover, podocyte injury is the key pathological change of PNS. Even though the pathophysiological etiology of PNS has not been fully understood, the production of excessive reactive oxygen species (ROS) plays an important role in the development and progression of the disease. Glucocorticoids are the first-line medications for patients with PNS, but their clinical use is hampered by dose-dependent side effects. Herein, we accelerated the rate of conversion from Ce

resultsThe engineered Ce

conclusion7CZ nanomedicines were highly effective in protecting against ADR-induced podocyte injury in vitro and in vivo at a very low concentration.

Indexed as

Nephrotic SyndromePodocytesAnimalsAntioxidantsDoxorubicinHumansNanomedicineRatsReactive Oxygen SpeciesZirconiumAntioxidantsDoxorubicinReactive Oxygen SpeciesZirconiumzirconium oxideCeria-zirconia nanoparticlesPodocytePrimary nephrotic syndromeReactive oxygen species

Identifiers

PMID37858242
PMCPMC10588015
OpenAlexW4387782177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.